About Sigilon Therapeutics, Inc.
Sigilon Therapeutics Inc. is a clinical-stage biotechnology company seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company has developed its SLTx platform, which combines advanced cell engineering with advancements in biocompatible materials and enables its product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies and enzymes. The Company’s lead product candidate is SIG-001, which is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia. The Company’s other product candidates includes SIG-009, SIG-003, SIG-005, SIG-007, SIG-018, SIG-002, SIG-014 and SIG-015.